Skip to main content
Lincoln Pharmaceuticals ltd. logo

Lincoln Pharmaceuticals ltd. — Investor Relations & Filings

Ticker · LINCOLN ISIN · INE405C01035 LEI · 3358004B6OBJNW8RTT10 BSE.NS Manufacturing
Open in API
Filings indexed 451 across all filing types
Latest filing 2026-05-28 Earnings Release
Country IN India
Listing BSE.NS LINCOLN

About Lincoln Pharmaceuticals ltd.

https://www.lincolnpharma.com/

Lincoln Pharmaceuticals Ltd. focuses on the development, manufacturing, and marketing of a diverse range of therapeutic formulations. The organization operates advanced manufacturing facilities certified by international standards, including WHO-GMP. Its portfolio spans multiple areas such as anti-infectives, cardiovascular, gastrointestinal, respiratory, and pain management. The company is recognized for its research and development initiatives, particularly in Novel Drug Delivery Systems (NDDS). Key offerings include specialized treatments for tinnitus and a wide array of formulations in dosage forms like tablets, capsules, liquid orals, and injectables. It maintains a significant global footprint, supplying products to numerous international markets across Africa, Southeast Asia, and Latin America, supported by a robust distribution network for its extensive healthcare catalog.

Recent filings

Filing Released Lang Actions
Dividend
Earnings Release Classification · 78% confidence The document is the Company’s formally issued “Outcome of Board Meeting” announcing the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2026, including a full set of income statements, balance sheet and cash flow statements, along with the auditors’ unmodified opinion. This is a periodical financial results announcement to the stock exchanges. It is not a full Annual Report (10-K) or merely a notice of report publication, nor is it an interim report (IR covers periods shorter than a full year). Therefore, the filing best matches an Earnings Release (ER). FY 2026
2026-05-28 English
Recommended a Final Dividend of Rs. 1.80/- (i.e 18%) per equity share of face value Rs. 10/- each for the financial year ended March 31, 2026 subject to approval of the members at the ensuing ....
Interim / Quarterly Report Classification · 82% confidence The document is the formal exchange filing of the company’s audited financial results under SEBI Listing Regulations, containing full standalone income statement, balance sheet, cash flows and notes for the quarter and year ended March 31, 2026. It is not a brief earnings summary (ER), nor a narrative annual report (10-K). It is a periodical financial report submitted to satisfy quarterly/half-year/year-end obligations, fitting the Interim/Quarterly Report category (IR). FY 2026
2026-05-28 English
Audited Financial Results for the Quarter and Year ended March 31, 2026.
Interim / Quarterly Report Classification · 96% confidence The document is a stock‐exchange filing under SEBI LODR Regulations (Regulation 30 & 33) titled “Outcome of Board Meeting,” enclosing the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, including full P&L, balance sheet, cash flow statements and notes. It is not a mere announcement of publication but contains the substantive financial statements itself. This matches the definition of an Interim/Quarterly Report (IR) as it provides comprehensive financial results for the quarter (and the corresponding year‐to‐date period) with actual statements. FY 2026
2026-05-28 English
Outcome of Board Meeting
Interim / Quarterly Report Classification · 90% confidence The document is a Board Meeting outcome notice filed under SEBI Listing Regulations, which encloses and includes the full audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2026 along with balance sheet, cash flow statement, notes, and auditors’ report. It contains actual financial statements and substantive financial data. It is not a full Annual Report proxy or narrative 10-K, nor is it merely an announcement of a report’s availability. Therefore, it best fits the definition of an Interim/Quarterly Report (IR). FY 2026
2026-05-28 English
Outcome of Board Meeting for Audited Financial Results for the Quarter and Year Ended 31st March, 2026.
Interim / Quarterly Report Classification · 85% confidence The document is a formal SEBI listing regulation filing titled “Outcome of Board Meeting,” addressed to the NSE and BSE, enclosing the “Statement of Audited Standalone Financial Results for the Quarter and Year Ended March 31, 2026.” It includes full financial tables (income statement, balance sheet, cash flows) and audit opinions for a quarter period (Q4) with year-to-date figures. It is not a full annual report (10-K), mere highlights (ER), nor just an announcement (RPA). It is a periodic interim/quarterly statutory results release under Regulation 33, so it falls under the Interim / Quarterly Report category. FY 2026
2026-05-28 English
Meeting of the Board of Directors is scheduled to be held on May 28, 2026 to consider and approve Audited Financial Results of the Company and recommendation of Dividend on equity shares ....
Regulatory Filings Classification · 89% confidence The document is a formal notice under SEBI LODR Regulation 29 to the stock exchanges, informing investors of a forthcoming Board of Directors meeting to approve audited financial results and consider dividends. It does not itself contain the financial results (so it is not an earnings release or financial report), nor is it a change in board composition. It is a routine regulatory announcement. No specific category covers “Board meeting notice,” so it falls under the general regulatory filings catch-all. Thus RNS is appropriate.
2026-05-18 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.